Tango Therapeutics Files Initial Ownership Statement
Ticker: TNGX · Form: 3 · Filed: Apr 24, 2026 · CIK: 0001819133
Sentiment: neutral
Topics: insider-filing, ownership, disclosure
Related Tickers: TNGX
TL;DR
Tango Therapeutics (TNGX) filed a Form 3 on 4/24/26 - initial ownership disclosure.
AI Summary
On April 24, 2026, Tango Therapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates a change in the beneficial ownership of securities for the company, which is involved in the pharmaceutical preparations industry. The report period for this change was April 15, 2026.
Why It Matters
This filing marks an initial disclosure of beneficial ownership for Tango Therapeutics, Inc., providing transparency on who holds significant stakes in the company.
Risk Assessment
Risk Level: low — A Form 3 filing is a routine disclosure of beneficial ownership and does not inherently indicate financial distress or significant operational changes.
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Issuer
- 0001819133 (company) — Issuer CIK
- Gall Matthew (person) — Reporting Person
- 0001816194 (person) — Reporting Person CIK
- ITEOS THERAPEUTICS, INC. (company) — Mailing Address Recipient
FAQ
What type of SEC filing is this?
This is a Form 3, an initial statement of beneficial ownership of securities.
When was the filing date?
The filing date was April 24, 2026.
What is the reporting period for this filing?
The period of report was April 15, 2026.
What is the CIK for Tango Therapeutics, Inc.?
The CIK for Tango Therapeutics, Inc. is 0001819133.
Who is listed as the reporting person in the mailing address section?
Gall Matthew is listed as the reporting person in the mailing address section.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 24, 2026 by Gall Matthew regarding Tango Therapeutics, Inc. (TNGX). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.